 OCALA, Fla., April 07, 2021 GLOBE NEWSWIRE -- AIM ImmunoTech Inc. NYSE American: AIM today announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIMs drug Ampligen as an intranasal therapy, reporting no serious adverse events, and paving the way for escalation of the dose in Cohort 2. The trial is a critical step in the companys ongoing efforts to develop Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases. 